Navigation Links
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Date:3/30/2011

SHELTON, Conn., March 30, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the appointment of James B. Jones, M.D., Pharm.D., to the position of Chief Medical Officer.  In this role, Dr. Jones will oversee the ongoing clinical development of Cara's lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid agonist, which is currently in Phase 2 development for treatment of post-operative pain.

"We are delighted to add someone of Jim's clinical background and drug development experience to the Cara team," said Derek Chalmers, President and CEO of Cara Therapeutics.  "We look forward to benefiting from his considerable success in developing novel analgesics as we continue the clinical development of CR845."

Dr. Jones most recently was the Chief Medical Officer at Strativa Pharmaceuticals, a division of Par Pharmaceuticals, Inc. Previously, he was the VP of Clinical Development and Medical Affairs at Xanodyne Pharmaceuticals where he was instrumental in the approval and subsequent launch of Zipsor™ (diclofenac potassium).  Prior to Xanodyne, Dr. Jones was VP of Clinical Development at Alpharma Pharmaceuticals where he was actively involved in the development of EMBEDA™ (morphine sulfate and naltrexone hydrochloride). Other analgesics/CNS compounds that Dr. Jones has worked on include Lusedra (fospropofol disodium) while at Guilford Pharmaceuticals as well as valdecoxib and parecoxib while at Pharmacia. Dr. Jones received his Doctorate of Medicine degree from the University of Pennsylvania and his Doctorate of Pharmacy from Purdue University.

"I am very enthusiastic to join Cara and to be involved in the clinical development of CR845," said Dr. Jones.  "I believe that CR845 has the potential to fill an important unmet medical need in the pain field and could serve as a new first-in-class and best-in-class peripherally acting kappa opioid agonist for the treatment of both acute post-op pa
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
2. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
4. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
5. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
6. Reportlinker Adds Therapeutics for Immune System Disorders
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
9. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
10. Echo Therapeutics Announces 2010 Financial Results
11. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
(Date:9/22/2014)... Sept. 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... initiated a phase I clinical trial in patients ... safety, tolerability, and immunogenicity of INO-3106. This immunotherapy ... most aerodigestive cancers. Aerodigestive cancers affect ... and parts of the esophagus and windpipe. The ...
(Date:9/22/2014)... , Sept. 22, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... pleased to announce that TUV-SUD and The Medicinal ... (MEB) has granted its request for a ... Neutrolin was initially approved in July 2013 for ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... 2014 (HealthDay News) -- Two new prescription devices approved ... provide some relief for people with migraine headaches who ... study. One device -- the Cefaly -- is ... the Cerena -- is meant to be used when ... "Patients have been looking for alternative migraine treatments. ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
Breaking Medicine News(10 mins):Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... SETO Holdings, Inc. (Pink Sheets: SETO) announced that it signed ... (1) to issue shares of its Common Stock to acquire ... ("AHC"), a Maryland corporation which provides hearing services and retails ... Virginia, and (2) to sell all of SETO,s current businesses, ...
... how that happens may lead to ways around it, ... Temozolomide, a standard treatment for brain cancer, may boost ... more likely, a new study suggests. , The research ... City, have identified cells in brain tumors called gliomas ...
... Company Records 172% Year over Year Revenue Growth and ... Insulet,s International ExpansionBrian Roberts Appointed CFOBEDFORD, Mass., March 5 ... leader in tubing-free insulin pump technology with its OmniPod(R) ... fourth quarter and full year ended December 31, 2008. ...
... SEATTLE, March 5 Trubion Pharmaceuticals Inc. (Nasdaq: ... issue earnings results for the fourth quarter and year ... on March 12, 2009. The company,s earnings conference call ... Pacific Time, 5 p.m. Eastern Time. Both live events ...
... editors of the Harvard Health Letter , in consultation with the ... health care spending, saving society--and perhaps yourself--some money , ... Boston, MA ... will falter unless health care spending is brought under control. Moreover, even ...
... OpportunitiesHARRISBURG, Pa., March 5 Insurance Commissioner ... off from a job that offered health insurance to ... them with relief on premiums and that now is ... want to let Pennsylvanians know that additional help in ...
Cached Medicine News:Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 2Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 4Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 5Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 6Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 7Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 8Health News:Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 3Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: